Mylan has head start on US Adcirca rival

Mylan has strengthened the firm’s cardiovascular portfolio in the US by launching the first generic of Eli Lilly’s Adcirca (tadalafil) 20mg tablets with 180 days of marketing exclusivity. The launch comes shortly after Mylan received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) referencing the treatment for pulmonary arterial hypertension to improve exercise ability.